rosiglitazone has been researched along with Acromegaly in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colao, A; Grasso, LF; Pivonello, R | 1 |
| Gruszka, A; Kunert-Radek, J; Pawlikowski, M; Radek, M; Winczyk, K; Ławnicka, H | 1 |
| Bogazzi, F; Cosci, C; Lombardi, M; Martino, E; Raggi, F; Rossi, G; Sardella, C; Urbani, C | 1 |
| Gradiser, M; Matovinovic, M; Vrkljan, M | 1 |
| Akin, F; Bastemir, M; Yaylali, GF | 1 |
1 review(s) available for rosiglitazone and Acromegaly
| Article | Year |
|---|---|
Investigational therapies for acromegaly.
Topics: Acromegaly; Dacarbazine; Drugs, Investigational; Human Growth Hormone; Humans; Octreotide; Pioglitazone; Rosiglitazone; Somatostatin; Temozolomide; Thiazolidinediones | 2013 |
2 trial(s) available for rosiglitazone and Acromegaly
| Article | Year |
|---|---|
Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study.
Topics: Acromegaly; Adult; Animals; Antineoplastic Agents, Hormonal; Female; Hep G2 Cells; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor I; Male; Middle Aged; Octreotide; Pilot Projects; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2011 |
The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
Topics: Acromegaly; Adenoma; Adult; Diabetes Mellitus; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor I; Male; Middle Aged; PPAR gamma; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Failure | 2007 |
2 other study(ies) available for rosiglitazone and Acromegaly
| Article | Year |
|---|---|
Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro.
Topics: Acromegaly; Adenoma; Adrenocorticotropic Hormone; Adult; Aged; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Female; Human Growth Hormone; Humans; Hypoglycemic Agents; Male; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Cells, Cultured | 2009 |
Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
Topics: Acromegaly; Adenoma; Adult; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Growth Hormone; Growth Hormone-Secreting Pituitary Adenoma; Humans; Insulin-Like Growth Factor I; Rosiglitazone; Thiazolidinediones | 2007 |